Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 53% Improvement Relative Risk Vitamin D for COVID-19  Kaufman et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 51,511 patients in the USA Fewer cases with higher vitamin D levels (p=0.001) c19early.org Kaufman et al., PLOS One, September 2020 Favors vitamin D Favors control

SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels

Kaufman et al., PLOS One, doi:10.1371/journal.pone.0239252
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Analysis of 191,779 patients in the US finding COVID-19 positivity strongly and inversely associated with circulating 25(OH)D levels. The relationship persists across latitudes, races/ethnicities, gender, and age ranges.
COVID-19 adjusted odds ratio OR 0.984 per ng/mL increment, p<0.001). The decrease in positivity rate appeared to plateau as values approached 55 ng/mL.
Patients with high D levels (>55 ng/mL) compared to patients with very low D levels (<20 ng/mL) have a much lower risk of COVID-19 cases, with unadjusted RR 0.47, p<0.001.
This is the 14th of 192 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 611 vigintillion).
risk of case, 53.0% lower, RR 0.47, p < 0.001, high D levels 12,321, low D levels 39,190, >55 ng/mL vs. <20 ng/mL.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kaufman et al., 17 Sep 2020, retrospective, population-based cohort, USA, peer-reviewed, median age 54.0, 5 authors.
This PaperVitamin DAll
SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels
Harvey W Kaufman, Justin K Niles, Martin H Kroll, Caixia Bi, Michael F Holick
PLOS ONE, doi:10.1371/journal.pone.0239252
Until treatment and vaccine for coronavirus disease-2019 (COVID-19) becomes widely available, other methods of reducing infection rates should be explored. This study used a retrospective, observational analysis of deidentified tests performed at a national clinical laboratory to determine if circulating 25-hydroxyvitamin D (25(OH)D) levels are associated with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) positivity rates. Over 190,000 patients from all 50 states with SARS-CoV-2 results performed mid-March through mid-June, 2020 and matching 25(OH)D results from the preceding 12 months were included. Residential zip code data was required to match with US Census data and perform analyses of race/ethnicity proportions and latitude. A total of 191,779 patients were included (median age, 54 years [interquartile range 40.4-64.7]; 68% female. The SARS-CoV-2 positivity rate was 9.3% (95% C.I. 9.2-9.5%) and the mean seasonally adjusted 25(OH)D was 31.7 (SD 11.7). The SARS-CoV-2 positivity rate was higher in the 39,190 patients with "deficient" 25(OH)D values (<20 ng/mL) (12.5%, 95% C.I. 12.2-12.8%) than in the 27,870 patients with "adequate" values (30-34 ng/mL) (8.1%, 95% C.I. 7.8-8.4%) and the 12,321 patients with values �55 ng/mL (5.9%, 95% C.I. 5.5-6.4%). The association between 25 (OH)D levels and SARS-CoV-2 positivity was best fitted by the weighted second-order polynomial regression, which indicated strong correlation in the total population (R 2 = 0.96) and in analyses stratified by all studied demographic factors. The association between lower SARS-CoV-2 positivity rates and higher circulating 25(OH)D levels remained significant in a multivariable logistic model adjusting for all included demographic factors (adjusted odds ratio 0.984 per ng/mL increment, 95% C.I. 0.983-0.986; p<0.001). SARS-CoV-2 positivity is strongly and inversely associated with circulating 25(OH)D levels, a relationship that persists across latitudes, races/ethnicities, both sexes, and age ranges. Our findings provide impetus to explore the role of vitamin D supplementation in reducing the risk for SARS-CoV-2 infection and COVID-19 disease.
Author Contributions Conceptualization: Harvey W. Kaufman, Justin K. Niles, Martin H. Kroll
References
Berry, Hesketh, Power, Hypponen, Vitamin D status has a linear association with seasonal infections and lung function in British adults, The British Journal of Nutrition, doi:10.1017/S0007114511001991
Bhala, Curry, Martineau, Agyemang, Sharpening the global focus on ethnicity and race in the tie of COVID-19, Lancet, doi:10.1016/S0140-6736%2820%2931102-8
D'avolio, Avataneo, Manca, 25-Hydroxyvitamin D Concentrations are Lower in Patients with Positive PCR for SARS-CoV-2, Nutrients, doi:10.3390/nu12051359
Grant, Lahore, Mcdonnell, Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths, Nutrients
Gunville, Mourani, Ginde, The role of vitamin D in prevention and treatment of infection, Inflamm Allergy Drug Targets, doi:10.2174/18715281113129990046
Hastie, Mackay, Ho, Vitamin D concentrations and COVID-19 infection in UK Biobank, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.050
Holick, Binkley, Bischoff-Ferrari, Evaluation, Treatment & Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, doi:10.1210/jc.2011-0385
Ingham, Jones, Camargo, Study, G. Association of vitamin D deficiency with severity of acute respiratory infection: A case-control study in New Zealand children, European Respiratory Journal
Kohlmeier, Avoidance of vitamin D deficiency to slow the COVID-19 pandemic, BMJ Nutrition, Prevention & Health, doi:10.1136/bmjnph-2020-000096
Kroll, Bi, Garber, Temporal Relationship between Vitamin D Status and Parathyroid Hormone in the United States, PloS ONE, doi:10.1371/journal.pone.0118108
Martineau, Jolliffe, Hooper, Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ, doi:10.1136/bmj.i6583
Mehta, Mcauley, Brown, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736%2820%2930628-0
Panarese, Shahini, Letter: Covid-19, and vitamin D, Aliment Pharmacol Ther, doi:10.1111/apt.15752
Rhodes, Dunstan, Laird, COVID-19 mortality increases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin D, BMJ Nutrition, Prevention & Health, doi:10.1136/bmjnph-2020-000110
Sabetta, Depetrillo, Cipriani, Smardin, Burns et al., Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults, PLoS One, doi:10.1371/journal.pone.0011088
Yancy, COVID-19 and African Americans, JAMA, doi:10.1001/jama.2020.6548
Zdrenghea, Makrinioti, Bagacean, Bush, Johnston et al., Vitamin D modulation of innate immune responses to respiratory viral infections, Rev Med Virol, doi:10.1002/rmv.1909
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit